You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Dow
Johnson and Johnson
Harvard Business School
McKesson

Last Updated: June 3, 2020

DrugPatentWatch Database Preview

Litigation Details for HOFFMANN-LA ROCHE INC. v. APOTEX INC. (D.N.J. 2007)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

HOFFMANN-LA ROCHE INC. v. APOTEX INC. (D.N.J. 2007)

Docket   Start Trial Date Filed 2007-09-14
Court District Court, D. New Jersey Date Terminated 2012-11-16
Cause 35:271 Patent Infringement Assigned To Stanley R. Chesler
Jury Demand None Referred To Magistrate Judge Cathy L. Wald
Parties APOTEX CORP.; APOTEX INC.; GENENTECH, INC.; HOFFMAN-LA ROCHE INC.; HOFFMANN-LA ROCHE, INC.; PHV ROBERT B. BREISBLATT
Patents 4,621,077; 4,927,814; 6,143,326; 6,294,196; 6,432,932; 7,192,938; 7,410,957; 7,718,634
Attorneys DAVID E. DELORENZI; JOSHUA HARLAN HARRIS; MARK E. WADDELL; PAUL BRIAN SUDENTAS; PAULA K. COLBATH; SHEILA F. MCSHANE; STEVEN GERBER
Link to Docket External link to docket
Small Molecule Drugs cited in HOFFMANN-LA ROCHE INC. v. APOTEX INC.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for HOFFMANN-LA ROCHE INC. v. APOTEX INC. (D.N.J. 2007)

Date Filed Document No. Description Snippet Link To Document
2007-09-14 1 U.S. Patent No. 6,294,196, expiring October 7, 2019. Notwithstanding the United States Patent and … is an action for patent infringement arising under the Food and Drug and Patent Laws of the United…companies to submit patent information to the FDA “with respect to which a claim of patent infringement …prior to patent expiration by stating in its ANDA that it challenges whether the listed patent is “invalid…expiration of two Roche patents listed in the Orange Book, namely U.S. Patent External link to document
2010-05-10 174 terms in U.S. Patent Nos. 4,927,814 (the “’814 patent”), 7,192,938 (the “’938 patent”), and 7,410,957938 patent. Counsel for Roche has advised the Court that, while this eliminates the ’938 patent from… It is a bedrock principle of patent law that the claims of a patent define the invention to…in the ’814 patent The parties dispute terms in three claims of the ’814 patent: 4…disconnected from the ’814 patent and what the inventor invented. The patent is directed to the part of External link to document
2010-05-07 175 Signed by Judge Stanley R. Chesler… and ’957 patents, the Court concludes that the claim terms in claim 1 of the ’938 patent, “commencing…stated in that Opinion. As to the ’814 patent, the disputes are resolved as follows: 1) the claim…,” and the similar terms in claim 1 of the ’957 patent, should be construed to refer to the time frame External link to document
2010-08-24 251 11 PageID: 15530 owns U.S. Patent No. 4,927,814 (the “’814 patent”), which is directed to certain…Procedure 56, that Defendants infringe the ’814 patent by Plaintiff Hoffman-La Roche Inc. (“Roche”)…matter involves several Hatch-Waxman actions for patent infringement. The cases have been consolidated…of Boniva® prior to the expiration of Roche’s patent. … Literal infringement The test for patent infringement requires a two step analysis: “the External link to document
2010-09-02 257 Briefly, Roche owns the U.S. Patent No. 7,410,957 (the “’957 patent”), which is directed to methods…label to the FDA in 2007, the ’957 patent did not exist. Fine. The patent exists now. …summary judgment that Defendants infringe the ’957 patent by Plaintiff Hoffman-La Roche Inc. (“Roche”), against…summary judgment of non-infringement of the ’957 patent by Defendant DRL; 3) the cross- motion for summary…summary judgment of non-infringement of the ’957 patent by Defendant Genpharm; and 4) the motion for External link to document
2010-09-02 259 Briefly, Roche owns the U.S. Patent No. 7,410,957 (the “’957 patent”), which is directed to methods…label to the FDA in 2007, the ’957 patent did not exist. Fine. The patent exists now. …summary judgment that Defendants infringe the ’957 patent by Plaintiff Hoffman-La Roche Inc. (“Roche”), against…summary judgment of non-infringement of the ’957 patent by Defendant DRL; 3) the cross- motion for summary…summary judgment of non-infringement of the ’957 patent by Defendant Genpharm; and 4) the motion for External link to document
2010-09-30 271 facts. Briefly, Roche owns U.S. Patent No. 4,927,814 (the “’814 patent”), which is directed to certain…for summary judgment, by Apotex, that the 4,927,814 patent is unenforceable based on inequitable conduct…Roche’s patent. Defendants have answered Roche’s claim of infringement of the ’814 patent with …judgment of no inequitable conduct as to the ’814 patent by Plaintiff Hoffman-La Roche Inc. (“Roche”), against…matter involves several Hatch-Waxman actions for patent infringement. The cases have been consolidated External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Harvard Business School
Express Scripts
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.